HomepageEarnings Events Newsdesk 2 hours ago Synopsys, Inc (SNPS) Sec Form 8K Synopsys, Inc (NASDAQ: SNPS) Sec Form 8K Royal Gold, Inc (RGLD) Sec Form 10K » « Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer Newsdesk: